Purdue researchers apply new technique to manipulate virus, make it a possible cancer treatment
November 27, 2013
WEST LAFAYETTE, Ind. — Purdue University researchers successfully eliminated the native infection preferences of a Sindbis virus engineered to target and kill cancer cells, a milestone in the manipulation of this promising viral vector.
"This virus had been known to be a good vector for delivering therapeutic cargo, however it naturally infected all kinds of cells, and these diversions would compete with what we were instructing it to target," said Richard Kuhn, the Gerald and Edna Mann Director of Purdue's Bindley Biosciences Center. "We have now overcome a major challenge by not only inserting a targeting molecule of our choice, but also successfully stripping the virus of its native entry preferences. This was a big step in unlocking the potential of developing this virus into a platform for both targeted drug delivery, where it would sneak drugs inside cancer cells, and oncolytic virotherapy, where the virus itself destroys cancer cells."
- Elizabeth K. Gardner, Writer
May 1, 2015
A Purdue University professor has been elected into the National Academy of Sciences, one of the highest honors given to a scientist in the United States.Read Full Story
April 30, 2015
A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment.Read Full Story
April 16, 2015
Searching for compounds to produce new or better drugs is like looking for a needle in a haystack, with inefficient screening for identification and characterization of effective new drug compounds directly impacting the cost of drug development (now in excess of $1 billion per drug).Read Full Story